Opinion

Video

Current and Emerging Treatment Landscape of mHSPC

Author(s):

Jack R. Andrews, MD,Eugene B. Cone, MD

Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Timecodes

      1:54 mHSPC and Imaging

      4:57 Current SOC in mHSPC

      10:15 Choosing Therapy in mHSPC

      18:51 ARANOTE Trial in mHSPC

      21:15 Experience With ARI

      27:08 Emerging mHSPC Treatments

      32:51 ARANOTE Subgroup Analysis

      35:31 Future Outlook for mHSPC

      Related Videos
      Checkpoint Inhibitors for Treatment of NMIBC
      Checkpoint Inhibitors for Treatment of NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      3 experts are featured in this series.
      Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
      3 experts are featured in this series.
      Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
      1 expert in this video
      BPH: The Patient Journey
      Addressing Remaining Unmet Needs in mCRPC
      Addressing Remaining Unmet Needs in mCRPC
      Use and Sequencing of Novel Treatments in NMIBC
      Use and Sequencing of Novel Treatments in NMIBC
      The DORA Trial
      The DORA Trial
      FDA-Approved Treatments for BCG-Unresponsive NMIBC
      FDA-Approved Treatments for BCG-Unresponsive NMIBC
      Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
      Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
      Related Content
      US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
      February 4th 2025

      FDA Updates in Urology: January 2025

      Patrick Campbell
      A recap of the FDA submissions and regulatory decisions in urology from January 2025.
      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
      January 14th 2025

      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

      Wayne Kuang, MD Steven Maislos, MD
      Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
      doctor holding a pen talking to patient
      December 14th 2022

      Study finds only half of patients undergoing 24-hour urine tests receive complete testing

      Hannah Clarke
      “One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.
      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
      November 27th 2024

      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

      Wayne Kuang, MD Bilal Chughtai, MD
      Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
      Doctor discusses treatment information with patient
      October 19th 2022

      Study finds inadequate patient education for scheduled urologic procedures

      Hannah Clarke
      Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.
      First European patient treated for urethral stricture with novel drug-coated balloon catheter
      February 2nd 2021

      First European patient treated for urethral stricture with novel drug-coated balloon catheter

      Jason M. Broderick
      The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.
      © 2025 MJH Life Sciences

      All rights reserved.